Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer and / or Hematological Malignancy”

652 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 652 results

Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Not applicableEnrolling By InvitationNCT04202094
What this trial is testing

Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems

Who this might be right for
Childhood CancerHematological Disorders
Universitair Ziekenhuis Brussel 50
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Very early researchUnknownNCT04700319
What this trial is testing

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

Who this might be right for
CAR
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 30
Post-approval studies (Phase 4)Active Not RecruitingNCT02386800
What this trial is testing

CINC424A2X01B Rollover Protocol

Who this might be right for
Primary MyelofibrosisPolycythemia VeraGraft Versus Host Disease+2 more
Novartis Pharmaceuticals 279
Early research (Phase 1)Ended earlyNCT03135028
What this trial is testing

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Who this might be right for
Hematologic MalignancyAcute Myeloid Leukemia
Gilead Sciences 9
Large-scale testing (Phase 3)Study completedNCT02116530
What this trial is testing

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Who this might be right for
Hematopoietic/Lymphoid CancerNausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
Alliance for Clinical Trials in Oncology 401
Testing effectiveness (Phase 2)Study completedNCT03128359
What this trial is testing

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Who this might be right for
Acute LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Myelogenous Leukemia, BCR-ABL1 Positive+12 more
City of Hope Medical Center 38
Testing effectiveness (Phase 2)Study completedNCT00381550
What this trial is testing

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous Leukemia+7 more
National Cancer Institute (NCI) 35
Early research (Phase 1)Looking for participantsNCT05735184
What this trial is testing

Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Who this might be right for
Acute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
Kura Oncology, Inc. 420
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Early research (Phase 1)UnknownNCT05415098
What this trial is testing

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Who this might be right for
Nasopharyngeal CarcinomaCastrate Resistant Prostate CancerGastric Cancer+6 more
Ascentage Pharma Group Inc. 90
Early research (Phase 1)Study completedNCT00741234
What this trial is testing

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Who this might be right for
Solid TumorsHematologic MalignanciesMyelodysplastic Syndrome
S*BIO 85
Testing effectiveness (Phase 2)Study completedNCT04205409
What this trial is testing

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more
University of Washington 20
Early research (Phase 1)Active Not RecruitingNCT04013685
What this trial is testing

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic Syndromes+3 more
Orca Biosystems, Inc. 155
Early research (Phase 1)Ended earlyNCT00089089
What this trial is testing

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Who this might be right for
Hematopoietic/Lymphoid CancerUnspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)UnknownNCT05028478
What this trial is testing

CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid TumorHematologic Malignancies
Curon Biopharmaceutical (Australia) Co Pty Ltd 164
Very early researchActive Not RecruitingNCT06765876
What this trial is testing

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Who this might be right for
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic 18
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Large-scale testing (Phase 3)Looking for participantsNCT05786716
What this trial is testing

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Who this might be right for
Haematological MalignancyColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK 30
Next Page